Your browser doesn't support javascript.
loading
OPEC study: An international multicenter study of ovarian preservation in endometrial cancers.
Akgor, Utku; Ayhan, Ali; Shushkevich, Alexander; Ozdal, Bulent; Angelou, Kyveli; Akbayir, Ozgur; Kaidarova, Dilyara; Ulrikh, Elena; Stepanyan, Artem; Ortac, Firat; Aliyev, Shamistan; Ozgul, Nejat; Taranenka, Siarhei; Haberal, Ali; Salman, Coskun; Seyhan, Alper; Selcuk, Ilker; Haidopoulos, Dimitrios; Akilli, Huseyin; Bolatbekova, Raikhan; Alaverdyan, Areg; Taskin, Salih; Murshudova, Sabina; Batur, Meltem; Berlev, Igor; Gultekin, Murat.
Afiliación
  • Akgor U; Department of Gynecologic Oncology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
  • Ayhan A; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Faculty of Medicine, Baskent University, Ankara, Turkey.
  • Shushkevich A; Department of Gynecologic Oncology, N.N. Alexandrov Cancer Center of Belarus, Minsk, Belarus.
  • Ozdal B; Department of Gynecologic Oncology, Ankara, Turkey.
  • Angelou K; Gynecologic Oncology Unit, 1st Department of Obstetrics and Gynecology, Alexandra Hospital, University of Athens, Athens, Greece.
  • Akbayir O; Department of Gynecologic Oncology, Kanuni Sultan Süleyman Training and Research Hospital, Istanbul, Turkey.
  • Kaidarova D; Oncogynecology Center, Kazakh Institute of Oncology and Radiology, Almaty, Kazakhstan.
  • Ulrikh E; North-Western State Medical University, N.N. Petrov Research Institute of Oncology, Saint-Petersburg, Russian Federation.
  • Stepanyan A; Department of Gynecologic Oncology, NAIRI Medical Center, Yerevan, Armenia.
  • Ortac F; Division of Gynaecologic Oncology, Department of Obstetrics and Gynaecology, School of Medicine, Ankara University, Ankara, Turkey.
  • Aliyev S; National Center of Oncology, Baku, Azerbaijan.
  • Ozgul N; Department of Gynecologic Oncology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
  • Taranenka S; Department of Gynecologic Oncology, N.N. Alexandrov Cancer Center of Belarus, Minsk, Belarus.
  • Haberal A; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Faculty of Medicine, Baskent University, Ankara, Turkey.
  • Salman C; Department of Gynecologic Oncology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
  • Seyhan A; Department of Gynecologic Oncology, Kanuni Sultan Süleyman Training and Research Hospital, Istanbul, Turkey.
  • Selcuk I; Department of Gynecologic Oncology, Ankara, Turkey.
  • Haidopoulos D; Gynecologic Oncology Unit, 1st Department of Obstetrics and Gynecology, Alexandra Hospital, University of Athens, Athens, Greece.
  • Akilli H; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Faculty of Medicine, Baskent University, Ankara, Turkey.
  • Bolatbekova R; Oncogynecology Center, Kazakh Institute of Oncology and Radiology, Almaty, Kazakhstan.
  • Alaverdyan A; Department of Gynecologic Oncology, NAIRI Medical Center, Yerevan, Armenia.
  • Taskin S; Division of Gynaecologic Oncology, Department of Obstetrics and Gynaecology, School of Medicine, Ankara University, Ankara, Turkey.
  • Murshudova S; National Center of Oncology, Baku, Azerbaijan.
  • Batur M; Department of Gynecologic Oncology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
  • Berlev I; North-Western State Medical University, N.N. Petrov Research Institute of Oncology, Saint-Petersburg, Russian Federation.
  • Gultekin M; Department of Gynecologic Oncology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
Int J Gynaecol Obstet ; 159(2): 550-556, 2022 Nov.
Article en En | MEDLINE | ID: mdl-35323994
ABSTRACT

OBJECTIVE:

To evaluate the feasibility and oncological safety of ovarian preservation in early stage endometrial adenocarcinoma (EC) patients aged 40 and below.

METHODS:

A total of 11 institutions from eight countries participated in the study. 169 of 5898 patients aged ≤40 years were eligible for the study. Patients with EC treated between March 2007 and January 2019 were retrospectively assessed.

RESULTS:

The median duration of follow-up after EC diagnosis was 59 months (4-187). Among 169 participants, ovarian preservation surgery (OPS) was performed in 54 (31.9%), and BSO was performed in 115 (68.1%) patients. Although patients younger than 30 years of age were more likely to have OPS than patients aged 30 to 40 years (20.4% vs. 9.6%, P = 0.021), there was no significant difference by the mean age. There were no other relevant baseline differences between OPS and BSO groups. The Kaplan-Meier analysis revealed no difference in either the overall survival (P = 0.955) or recurrence-free survival (P = 0.068) among patients who underwent OPS, and BSO.

CONCLUSION:

OPS appears to be safe without having any adverse impact on survival in women aged ≤40 years with FIGO Stage I EC.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Neoplasias Endometriales / Preservación de la Fertilidad Tipo de estudio: Observational_studies Límite: Adult / Female / Humans Idioma: En Revista: Int J Gynaecol Obstet Año: 2022 Tipo del documento: Article País de afiliación: Turquía

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Neoplasias Endometriales / Preservación de la Fertilidad Tipo de estudio: Observational_studies Límite: Adult / Female / Humans Idioma: En Revista: Int J Gynaecol Obstet Año: 2022 Tipo del documento: Article País de afiliación: Turquía